FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912113570> ?p ?o ?g. }

• W2912113570 endingPage "1053" @default.
• W2912113570 startingPage "1044" @default.
• W2912113570 abstract "Background Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment of cancer-associated VTE. Methods Through linkage of nationwide Danish registries, we identified all adults with cancer-associated VTE initiating treatment with rivaroxaban, 2012-2017. We estimated rates and absolute risk of the primary outcome of recurrent VTE and major bleeding; all-cause mortality was studied as a secondary outcome. Results We identified 8901 patients with cancer-associated VTE of whom 476 (5.3%) redeemed a prescription for rivaroxaban within 30 days of VTE diagnosis (mean age 71.5 years, 41% females, 57% with pulmonary embolism). Median time from cancer diagnosis to rivaroxaban prescription was 31 days (interquartile range 12-73 days). Most frequent cancers were gastrointestinal (26.1%), genitourinary (23.3%), and hematological cancer (12.6%). Few had distant metastases (7.1%). At 6 months, recurrent VTE occurred in 6.1% (15.1 events per 100 person-years) with the highest absolute risks for genitourinary cancer (8.1%), gastrointestinal cancer (7.3%), and breast cancer (6.5%). Major bleeding occurred in 1.9% (5.3 events per 100 person-years), in particular, in genitourinary cancer (4.5%) and lung cancer (4.2%). Eighty deaths (17.8%) occurred during follow up. Conclusion In this clinical practice setting, rivaroxaban was rarely used for cancer-associated VTE. However, among those who received rivaroxaban, the treatment appeared safe and effective with rates comparable to previous studies of selected populations." @default.
• W2912113570 created "2019-02-21" @default.
• W2912113570 creator A5056556806 @default.
• W2912113570 creator A5063647251 @default.
• W2912113570 creator A5072757201 @default.
• W2912113570 creator A5076999140 @default.
• W2912113570 creator A5078667862 @default.
• W2912113570 date "2019-02-14" @default.
• W2912113570 modified "2023-10-12" @default.
• W2912113570 title "Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study" @default.
• W2912113570 cites W1511423923 @default.
• W2912113570 cites W1551952385 @default.
• W2912113570 cites W1978670003 @default.
• W2912113570 cites W1984833612 @default.
• W2912113570 cites W2000445173 @default.
• W2912113570 cites W2015315066 @default.
• W2912113570 cites W2093389482 @default.
• W2912113570 cites W2097842790 @default.
• W2912113570 cites W2115019673 @default.
• W2912113570 cites W2115787552 @default.
• W2912113570 cites W2130199362 @default.
• W2912113570 cites W2135936995 @default.
• W2912113570 cites W2167494200 @default.
• W2912113570 cites W2174386486 @default.
• W2912113570 cites W2219591537 @default.
• W2912113570 cites W2225937646 @default.
• W2912113570 cites W2281570169 @default.
• W2912113570 cites W2317682010 @default.
• W2912113570 cites W2465074593 @default.
• W2912113570 cites W2467202497 @default.
• W2912113570 cites W2480010618 @default.
• W2912113570 cites W2524077168 @default.
• W2912113570 cites W2529469085 @default.
• W2912113570 cites W2537062802 @default.
• W2912113570 cites W2548586504 @default.
• W2912113570 cites W2551469077 @default.
• W2912113570 cites W2588687036 @default.
• W2912113570 cites W2604224928 @default.
• W2912113570 cites W2765286649 @default.
• W2912113570 cites W2775434460 @default.
• W2912113570 cites W2793035957 @default.
• W2912113570 cites W2795588879 @default.
• W2912113570 cites W2800976280 @default.
• W2912113570 cites W2802130786 @default.
• W2912113570 cites W2803489561 @default.
• W2912113570 cites W2884398655 @default.
• W2912113570 cites W2770833489 @default.
• W2912113570 doi "https://doi.org/10.1002/cam4.1997" @default.
• W2912113570 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6434207" @default.
• W2912113570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30767432" @default.
• W2912113570 hasPublicationYear "2019" @default.
• W2912113570 type Work @default.
• W2912113570 sameAs 2912113570 @default.
• W2912113570 citedByCount "12" @default.
• W2912113570 countsByYear W29121135702020 @default.
• W2912113570 countsByYear W29121135702021 @default.
• W2912113570 countsByYear W29121135702022 @default.
• W2912113570 countsByYear W29121135702023 @default.
• W2912113570 crossrefType "journal-article" @default.
• W2912113570 hasAuthorship W2912113570A5056556806 @default.
• W2912113570 hasAuthorship W2912113570A5063647251 @default.
• W2912113570 hasAuthorship W2912113570A5072757201 @default.
• W2912113570 hasAuthorship W2912113570A5076999140 @default.
• W2912113570 hasAuthorship W2912113570A5078667862 @default.
• W2912113570 hasBestOaLocation W29121135701 @default.
• W2912113570 hasConcept C119060515 @default.
• W2912113570 hasConcept C121608353 @default.
• W2912113570 hasConcept C126322002 @default.
• W2912113570 hasConcept C133507102 @default.
• W2912113570 hasConcept C141071460 @default.
• W2912113570 hasConcept C201903717 @default.
• W2912113570 hasConcept C207103383 @default.
• W2912113570 hasConcept C2776265017 @default.
• W2912113570 hasConcept C2776301958 @default.
• W2912113570 hasConcept C2778661090 @default.
• W2912113570 hasConcept C2779161974 @default.
• W2912113570 hasConcept C44249647 @default.
• W2912113570 hasConcept C530470458 @default.
• W2912113570 hasConcept C71924100 @default.
• W2912113570 hasConcept C72563966 @default.
• W2912113570 hasConceptScore W2912113570C119060515 @default.
• W2912113570 hasConceptScore W2912113570C121608353 @default.
• W2912113570 hasConceptScore W2912113570C126322002 @default.
• W2912113570 hasConceptScore W2912113570C133507102 @default.
• W2912113570 hasConceptScore W2912113570C141071460 @default.
• W2912113570 hasConceptScore W2912113570C201903717 @default.
• W2912113570 hasConceptScore W2912113570C207103383 @default.
• W2912113570 hasConceptScore W2912113570C2776265017 @default.
• W2912113570 hasConceptScore W2912113570C2776301958 @default.
• W2912113570 hasConceptScore W2912113570C2778661090 @default.
• W2912113570 hasConceptScore W2912113570C2779161974 @default.
• W2912113570 hasConceptScore W2912113570C44249647 @default.
• W2912113570 hasConceptScore W2912113570C530470458 @default.
• W2912113570 hasConceptScore W2912113570C71924100 @default.
• W2912113570 hasConceptScore W2912113570C72563966 @default.
• W2912113570 hasFunder F4320307771 @default.
• W2912113570 hasIssue "3" @default.
• W2912113570 hasLocation W29121135701 @default.

• next